BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare CV&Met: Atrial Fibrillation Market Spotlight

April 22, 2021

Atrial fibrillation (AF) is a common form of cardiac arrhythmia characterized by disordered electrical activity in the atria, which results in supraventricular tachyarrhythmia and ineffective contraction of the atria. Turbulent blood flow in the heart due to irregular rhythm increases the risk of forming thrombi in the atria, primarily in the left atrial appendage, that can result in an embolic stroke. There are several adverse events associated with AF such as systemic embolism, ischemic stroke, transient ischemic attack, and even death. Indeed, there is a five-fold increased risk of stroke in AF and a two-fold increase in mortality compared to non-AF patients.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Atrial Fibrillation/Flutter
Back to the top Back to the top